David M. Hammerbeck
7Patents
4h-index
10Co-inventors
46Inventor score
Filing activity: Oct 24, 1997 → Dec 2, 2004
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6039969A | Immune response modifier compounds for treatment of TH2 mediated and related diseases | Emerging Cross-Sectional Technologies | 284 | Expired |
| US6200592A | Immine response modifier compounds for treatment of TH2 mediated and related diseases | Emerging Cross-Sectional Technologies | 142 | Expired |
| US6696076B2 | Immune response modifier compounds for treatment of TH2 mediated and related diseases | Emerging Cross-Sectional Technologies | 111 | Expired |
| US6610319B2 | Immune response modifier compounds for treatment of TH2 mediated and related diseases | Emerging Cross-Sectional Technologies | 104 | Expired |
| US8110582B2 | Prophylactic treatment of UV-induced epidermal neoplasia | Human Necessities | 1 | Active |
| US8940755B2 | Therapeutic combinations and methods including IRM compounds | Human Necessities | 0 | Active |
| US8221771B2 | Formulations containing an immune response modifier | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.